-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a malignant plasma cell disease, accounting for about 10% of hematologic malignancies, second only to non-Hodgkin lymphoma, and more likely to occur in middle-aged and elderly people
.
In recent years, with the continuous advent of new drugs and the innovation of treatment methods, MM treatment has been gradually optimized and improved
.
In 2022, the Department of Hematology cooperated with a number of big coffee to discuss MM-related progress, and this issue of "Annual Inventory" selects and summarizes the interviews/reviews of MM experts in 2022, click on the article to read the original article
.
Bispecific antibodies1
2022 ASH Lessons from the Army | New therapies for myeloma: Talquetamab has an ORR of more than 70% for the treatment of multiple refractory myeloma
22022 ASH | Professor Xia Zhongjun: With the help of single and double antibodies, RRMM can be expected in the future
32022 EHA | Professor Niu Ting: The prospect of bispecific antibody therapy for RRMM is promising, and the combination with Dara creates more possibilities
2022ASH Voices | Professor Fu Weijun: Daratumumab contributes to the treatment of patients with multiple myeloma with renal insufficiency!
22022 ASH | Professor Jin Fengyan: The combination of four anti-CD38 monoclonal antibodies may solve the high-risk NDMM dilemma
32022 EHA Focused Monoclonal Antibody | Professor Fu Chengcheng: Daratumab treatment of newly diagnosed multiple myeloma data express
1
2022 EHA Professor Fu Weijun: Seliniso combined with dexamethasone brings effective remission to patients with R/R MM after CAR-T treatment
2Case sharing | Professor Zhang Xi commented: XPO1 inhibitor celinisol brings a new choice for patients with R/R MM with extramedullary lesions
3Case Sharing | Professor Wang Luqun commented: Targeted therapy has shown its strength, and the combination of celiniso has been used on the front line to bring relief to MM patients involved in CNS!
4Expert consensusProfessor Wu Depei, Professor Hu Yu and Professor Li Juan: The expert consensus on the clinical application of celiniso in multiple myeloma (2022) was officially released, helping to standardize the use of celiniso!
New options for RRMM patients, BCMA CAR-T clinical case sharing
1
EHA Reviews | Professor Huang Wenrong: Autologous NK cell therapy is safe and feasible as a first-line consolidation therapy after ASCT in patients with multiple myeloma, and it is worth exploring
1
EHA Interview | Professor Niu Ting: Novel proteasome inhibitors may change the treatment pattern of patients with relapsed/refractory multiple myeloma
22022 ASH Express | Professor Chen Wenming: The new generation of proteasome inhibitor carfilzomib has good efficacy and safe tolerance in the treatment of RRMM
Professor Huang Wenrong: Research progress of autologous hematopoietic stem cell transplantation in multiple myeloma with renal insufficiency2022 Chinese Hematology Conference
2Professor Wang Zhiguo: Autologous hematopoietic stem cell transplantation treatment for elderly multiple myeloma| The 7th International Summit Forum on Anti-leukemia and Lymphoma
Professor Wang Yafei: Clinical value of 1q abnormalities in MM
2Reviews | Professor Liu Aijun: Clinical significance of negative loss of minimal residual disease for multiple myeloma
32022CSH |Professor Sun Chunyan: Application and research progress of circulating tumor plasma cell detection in the clinical diagnosis and treatment of multiple myeloma
to treatment1
Professor Hu Yu: Focus on the quality of life of MM and go to the road of PRO-oriented treatment optimization
22022CSH | Professor Niu Ting: Based on the present and looking to the future, the development of multiple myeloma treatment in China
32022 SHS | Professor Fu Chengcheng: Jointly build a "blood think tank" to explore a new direction for MM diagnosis and treatment optimization
4Professor Fang Baijun: From the status quo to progress, look at the breakthrough of immunotherapy in R/R MM
5Professor Zhong Yuping | The era of immunotherapy: how to successfully break through the treatment of high-risk multiple myeloma?
62022 EMN Annual Meeting | Immunotherapy "blooms" to help MM precision treatment
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
